摘要
目的分析血清脂蛋白相关磷脂酶A2(Lp-PLA2)、白细胞介素(IL)-18、钙结合蛋白S100A8(S100A8)水平与糖尿病足溃疡(DFU)的关系。方法收集2019年1月至2021年3月于广州市番禺区中医院随诊的183例2型糖尿病(T2DM)患者的临床资料,按是否并发DFU分为T2DM组(101例)和DFU组(82例)。比较两组一般资料、Lp-PLA2、IL-18、S100A8等生化指标。探讨DFU发病的危险因素。结果DFU组空腹血糖、糖化血红蛋白水平高于T2DM组,糖尿病病程长于T2DM组(P<0.05)。DFU组Lp-PLA2、IL-18、S100A8、C反应蛋白、IL-1β、肿瘤坏死因子-α、白细胞计数、中性粒细胞百分比高于T2DM组(P<0.05)。logistic回归分析显示,IL-1β(OR=1.766,95%CI:1.332~2.343,P<0.001)、Lp-PLA2(OR=1.824,95%CI:1.294~2.571,P<0.001)、IL-18(OR=2.083,95%CI:1.367~3.175,P<0.001)、S100A8(OR=1.941,95%CI:1.211~3.112,P<0.001)升高均是DFU发病的危险因素。结论血清Lp-PLA2、IL-18、S100A8水平的升高与DFU的发病密切相关,可据此对高危DFU患者进行早期预防、诊治。
Objective To analyze the relationship between serum lipoprotein associated phospholipase A2(Lp-PLA2),interleukin(IL)-18,calcin binding protein S100A8(S100A8)and diabetic foot ulcers(DFU).Methods The clinical data of 183 patients with type 2 diabetes mellitus(T2DM)who were followed up in Panyu Hospital of Chinese Medicine from January 2019 to March 2021 were collected and they were divided into T2DM group(101 cases)and DFU group(82 cases)according to whether they were complicated with DFU.The differences of general clinical data,Lp-PLA2,IL-18,S100A8,and other biochemical indexes between the two groups were compared,and the risk factors of DFU were discussed.Results Fasting blood glucose and glycosylated hemoglobin levels in the DFU group were higher than those in the T2DM group,and diabetes duration in DFU group was longer than the T2DM group(P<0.05).Lp-PLA2,IL-18,S100A8,C-reactive protein,IL-1β,tumor necrosis factor-α,white blood cell count,and the proportion of neutrophils in DFU group were higher than those in T2DM group(P<0.05).Logistic regression analysis showed that,the increase of IL-1β(OR=1.766,95%CI:1.332-2.343,P<0.001),Lp-PLA2(OR=1.824,95%CI:1.294-2.571,P<0.001),IL-18(OR=2.083,95%CI:1.367-3.175,P<0.001),S100A8(OR=1.941,95%CI:1.211-3.112,P<0.001)were all risk factors for DFU.Conclusion The increase of serum Lp-PLA2,IL-18,and S100A8 levels is closely related to the pathogenesis of DFU,which can be used for early prevention,diagnosis and treatment of high-risk DFU patients.
作者
陈虹燕
龙可
黄淑莹
闵珊
CHEN Hongyan;LONG Ke;HUANG Shuying;MIN Shan(Department of Endocrinology,Panyu Hospital of Chinese Medicine,Guangdong Province,Guangzhou 511400,China)
出处
《中国医药导报》
CAS
2022年第18期63-66,74,共5页
China Medical Herald
基金
广东省中医药局科研项目(20181218)。
